Nektar Therapeutics (NKTR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting opened by Vice President, Legal and Corporate Counsel, with board members, executive team, and auditors present.
Formal business included voting on four proposals, followed by business highlights and a Q&A session.
Shareholder proposals
Four proposals: election of one director, amendment to increase shares in the 2017 Performance Incentive Plan, ratification of auditors, and a non-binding advisory vote on executive compensation.
Overview of voting outcomes
All four proposals were approved by a majority of shares voted, including director election, plan amendment, auditor ratification, and executive compensation.
Final results to be published in a Form 8-K within four business days.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Nektar Therapeutics
- Rezpegaldesleukin Phase 3 trials advance, backed by $1.02B cash and narrowed net loss.NKTR
Q2 2026 - Rezpegaldesleukin advances in late-stage trials for atopic dermatitis and alopecia, with strong financial runway.NKTR
H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025 - Global phase III trials for a novel Treg agonist target broad immune diseases, with first data in 2028.NKTR
Jefferies Global Healthcare Conference 2026 - Strong clinical progress, over $1B cash, and narrowed net loss support late-stage development.NKTR
Q1 2026 - Significant, durable hair regrowth and strong safety were achieved at 52 weeks in severe alopecia areata.NKTR
Study update - REZPEG advances to Phase 3 after strong Phase 2 data and $476M raised for late-stage trials.NKTR
Q4 2025 - Durable efficacy and safety maintained with monthly and quarterly dosing over 52 weeks.NKTR
Study result - REZPEG achieved significant hair regrowth and a favorable safety profile in severe alopecia areata.NKTR
Study Result - Q3 2024 saw stable revenue, narrowed net loss, and a $90M facility sale extending cash runway.NKTR
Q3 2024